SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

Will Next-Generation Modules be Enough to Differentiate Autolus’s Products? Ziopharm Deprioritizes Several Programs; What Targets and Indications Could Cellectis Pursue Next? Autolus, Ziopharm, and Cellectis Q1 2021 Earnings Call Summaries

Here is a brief preview of this blast: On Thursday, May 6, Autolus held their Q1 2021 earnings call (press release / presentation) highlighting several anticipated AUTO1 data updates in 2021 while providing details on their next-generation programs and manufacturing strategy. On the same day, Ziopharm presented their Q1 2021 results (press release / presentation) announcing the deprioritization of their controllable IL-12 gene therapy and their allogeneic CD19 RPM programs. Furthermore, Cellectis reported their Q1 2021 financial results (press release) commenting on the progress of their clinical program and a series of R&D events to be held between May 24 — 28.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.